Ashwin Kumar

Ashwin Kumar

Publications

Hide
Agrud A, Subburaju S, Goel P, Ren J, Kumar AS, Caldarone BJ, Dai W, Chavez J, Fukumura D, Jain RK, Kloner RA, Vasudevan A
Gabrb3 endothelial cell-specific knockout mice display abnormal blood flow, hypertension, and behavioral dysfunction.
Sci Rep. 2022;12(1):4922 - PMID: 35318369 - PMCID: PMC8941104 - DOI: 10.1038/s41598-022-08806-9
Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP, Roberge S, Ren J, Liu H, Chen IX, Andersson P, Chatterjee S, Kumar AS, Amoozgar Z, Zhang Q, Huang P, Ng MR, Chauhan VP, Xu L, Duda DG, Clark JW, Pittet MJ, Fukumura D, Jain RK
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Proc Natl Acad Sci U S A. 2021;118(45):ePub - PMID: 34725151 - PMCID: PMC8609309 - DOI: 10.1073/pnas.2105323118
Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, Lako A, Duda DG, Rodig SJ, Hodi FS, Jain RK
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
NPJ Precis Oncol. 2021;5(1):62 - PMID: 34188163 - PMCID: PMC8242049 - DOI: 10.1038/s41698-021-00197-w
Gomes-Santos IL, Amoozgar Z, Kumar AS, Ho WW, Roh K, Talele NP, Curtis H, Kawaguchi K, Jain RK, Fukumura D
Exercise training improves tumor control by increasing CD8+ T-cell infiltration via CXCR3 signaling and sensitizes breast cancer to immune checkpoint blockade.
Cancer Immunol Res. 2021;9(7):765-778 - PMID: 33839688 - PMCID: PMC8295193 - DOI: 10.1158/2326-6066.CIR-20-0499
Subburaju S, Kaye S, Choi YK, Baruah J, Datta D, Ren J, Kumar AS, Szabo G, Fukumura D, Jain RK, Elkhal A, Vasudevan A
NAD<sup>+</sup>-mediated rescue of prenatal forebrain angiogenesis restores postnatal behavior.
Sci Adv. 2020;6(41):ePub - PMID: 33036972 - PMCID: PMC7546698 - DOI: 10.1126/sciadv.abb9766
Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Proc Natl Acad Sci U S A. 2019;116(6):2210-2219 - PMID: 30659155 - PMCID: PMC6369817 - DOI: 10.1073/pnas.1818357116